OpenLB
Open Library of Bioscience
Advanced Search
BMC immunology
Dec 16, 2015;16 74.

Mesenchymal stromal cells to modulate immune reconstitution early post-hematopoietic cell transplantation.

Elizabeth O Stenger, Lakshmanan Krishnamurti, Jacques Galipeau
Author Information
  1. Elizabeth O Stenger: Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, 1405 Clifton Road, Atlanta, GA, 30322, USA. elizabeth.stenger@choa.org.
  2. Lakshmanan Krishnamurti: Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, 1405 Clifton Road, Atlanta, GA, 30322, USA. lakshmanan.krishnamurti@choa.org.
  3. Jacques Galipeau: Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, 1405 Clifton Road, Atlanta, GA, 30322, USA. jgalipe@emory.edu.
PMID: 26674007 DOI: 10.1186/s12865-015-0135-7

Abstract

Mesenchymal stromal cells (MSCs) are multipotent progenitor cells known to modulate the immune system and to promote hematopoiesis. These dual effects make MSCs attractive for use as cellular therapy in hematopoietic cell transplantation (HCT). MSCs can be used peri-HCT or pre-engraftment to modulate immune reconstitution, promoting hematopoietic stem cell (HSC) engraftment and/or preventing graft-versus-host disease (GVHD). Pre-clinical studies have demonstrated that MSCs can potentiate HSC engraftment and prevent GVHD in a variety of animal models. Clinical trials have been small and largely non-randomized but have established safety and early evidence of efficacy, supporting the need for larger randomized trials.

References

  1. Bone Marrow Transplant. 2009 Mar;43(6):447-54 [PMID: 18955980]
  2. Biol Blood Marrow Transplant. 2011 Feb;17(2):214-25 [PMID: 20816818]
  3. Blood. 2004 May 1;103(9):3313-9 [PMID: 14715641]
  4. Blood. 2004 Jun 15;103(12):4619-21 [PMID: 15001472]
  5. Nat Rev Immunol. 2012 May;12(5):383-96 [PMID: 22531326]
  6. Haematologica. 2003 Aug;88(8):845-52 [PMID: 12935972]
  7. Blood. 2005 Feb 15;105(4):1815-22 [PMID: 15494428]
  8. Mol Ther. 2012 Jan;20(1):187-95 [PMID: 21934657]
  9. Cell Death Differ. 2014 Mar;21(3):388-96 [PMID: 24162664]
  10. Bone Marrow Transplant. 2012 Sep;47(9):1186-90 [PMID: 22246086]
  11. Blood. 2006 Sep 15;108(6):2114-20 [PMID: 16690970]
  12. Bone Marrow Transplant. 2012 Mar;47(3):323-9 [PMID: 21552300]
  13. Haematologica. 2010 Apr;95(4):651-9 [PMID: 20179086]
  14. N Engl J Med. 2012 Dec 13;367(24):2305-15 [PMID: 23234514]
  15. Bone Marrow Transplant. 2011 Feb;46(2):200-7 [PMID: 20400983]
  16. Biol Blood Marrow Transplant. 2005 May;11(5):389-98 [PMID: 15846293]
  17. Cytotherapy. 2011 Mar;13(3):262-8 [PMID: 21231805]
  18. Biol Blood Marrow Transplant. 2008 Jan;14(1 Suppl 1):165-70 [PMID: 18162238]
  19. Blood. 2000 Jun 1;95(11):3620-7 [PMID: 10828053]
  20. Cytotherapy. 2012 Feb;14(2):147-52 [PMID: 22029655]
  21. Blood. 2005 Dec 15;106(13):4057-65 [PMID: 16118325]
  22. Blood. 2005 Mar 1;105(5):2214-9 [PMID: 15514012]
  23. Bone Marrow Transplant. 2013 Apr;48(4):537-43 [PMID: 23222384]
  24. Stem Cells. 2009 Sep;27(9):2293-300 [PMID: 19544531]
  25. Leukemia. 2008 Mar;22(3):593-9 [PMID: 18185520]
  26. Blood. 2007 Oct 1;110(7):2764-7 [PMID: 17638847]
  27. Exp Hematol. 2003 May;31(5):413-20 [PMID: 12763140]
  28. Cytotherapy. 2006;8(4):315-7 [PMID: 16923606]
  29. Cytotherapy. 2009;11(3):278-88 [PMID: 19308773]
  30. Exp Hematol. 2003 Oct;31(10):881-9 [PMID: 14550803]
  31. Stem Cells Dev. 2009 Nov;18(9):1247-52 [PMID: 19309241]
  32. Biol Blood Marrow Transplant. 2014 Apr;20(4):581-6 [PMID: 24370862]
  33. J Clin Oncol. 2000 Jan;18(2):307-16 [PMID: 10637244]
  34. Haematologica. 2014 Feb;99(2):346-52 [PMID: 24056821]
  35. Blood. 2004 Mar 1;103(5):1941-8 [PMID: 14592834]
  36. Hum Gene Ther. 2011 Jan;22(1):19-26 [PMID: 21028982]
  37. PLoS One. 2012;7(10):e47559 [PMID: 23133515]
  38. Exp Hematol. 2009 Oct;37(10):1250-1257.e1 [PMID: 19638293]
  39. Blood. 2003 May 1;101(9):3722-9 [PMID: 12506037]
  40. Cytotherapy. 2013 Jan;15(1):2-8 [PMID: 23260081]
  41. Biol Blood Marrow Transplant. 2012 Aug;18(8):1265-72 [PMID: 22343376]
  42. Biol Blood Marrow Transplant. 2011 Apr;17(4):465-75 [PMID: 20457265]
  43. Biol Blood Marrow Transplant. 2012 Apr;18(4):557-64 [PMID: 21820393]
  44. Biol Blood Marrow Transplant. 2012 Jun;18(6):822-40 [PMID: 21963621]
  45. Leukemia. 2007 Aug;21(8):1733-8 [PMID: 17541394]
  46. Exp Hematol. 2002 Aug;30(8):870-8 [PMID: 12160838]
  47. Stem Cells Transl Med. 2014 Aug;3(8):899-910 [PMID: 24904175]
  48. J Immunol. 2014 Feb 15;192(4):1491-501 [PMID: 24403533]

Grants

  1. KL2 TR000455/NCATS NIH HHS
  2. UL1 TR000005/NCATS NIH HHS
  3. UL1 TR000454/NCATS NIH HHS
  4. KL2TR000455/NCATS NIH HHS

MeSH Term

Animals
Clinical Trials as Topic
Graft Survival
Hematopoiesis
Hematopoietic Stem Cell Transplantation
Hematopoietic Stem Cells
Humans
Immunomodulation
Mesenchymal Stem Cell Transplantation
Mesenchymal Stem Cells
Models, Animal
Journal Article Research Support, N.I.H., Extramural Review
Article has an altmetric score of 2

Word Cloud

Created with Highcharts 10.0.0MSCscellsmodulateimmunecellMesenchymalstromalhematopoietictransplantationcanreconstitutionHSCengraftmentGVHDtrialsearlymultipotentprogenitorknownsystempromotehematopoiesisdualeffectsmakeattractiveusecellulartherapyHCTusedperi-HCTpre-engraftmentpromotingstemand/orpreventinggraft-versus-hostdiseasePre-clinicalstudiesdemonstratedpotentiatepreventvarietyanimalmodelsClinicalsmalllargelynon-randomizedestablishedsafetyevidenceefficacysupportingneedlargerrandomizedpost-hematopoietic

Similar Articles

Cited By